{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:02:46Z","timestamp":1789506166743,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["T32GM140935"],"award-info":[{"award-number":["T32GM140935"]}]},{"name":"NIH","award":["P50CA269011"],"award-info":[{"award-number":["P50CA269011"]}]},{"name":"NIH","award":["DP2 OD030734"],"award-info":[{"award-number":["DP2 OD030734"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) that combines AR antagonism and degradation via N-terminal domain binding, additionally targeting AR splice variants. In this study patients received ONCT-534 daily ranging from 40 to 1200\u00a0mg. The primary objectives were safety and dose-limiting toxicities (DLTs). Additional objectives included antitumor activity and AR signaling biomarkers. Adverse events (AEs) were assessed within the first 28\u00a0days for DLTs. Clinical activity was evaluated by PSA and radiographic progression per PCWG3 and RECIST v1.1. The trial was stopped early and not all patients were evaluated per protocol. Twenty-one patients received ONCT-534 across six doses. The most common AEs were anemia, back pain, and fatigue. While no DLTs were observed within 28\u00a0days, Grade 3\/4 AEs occurred later in 9 patients (anemia most frequently). One patient discontinued due to treatment-related AE. No radiographic or PSA-based responses were observed; however, three patients showed PSA declines at week 4, with one achieving a PSA50 at time of study closure. Of 10 patients with baseline AR protein data, the median change was\u2009\u2212\u200940.59% in AR protein levels at week 4. In the 300\u00a0mg cohort, 3 patients showed concordant decreases in AR protein and AR gene expression. Here, PSA levels correlated positively with AR target gene and AR gene expression. ONCT-534 had acceptable safety and demonstrated biological activity through AR protein degradation and AR signaling suppression in mCRPC patients. Although clinical responses weren\u2019t observed, these findings provide proof-of-concept for examining AR protein changes in patients receiving DAARIs.<\/jats:p>","DOI":"10.1007\/s10637-026-01600-8","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T04:20:00Z","timestamp":1772511600000},"page":"103-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534"],"prefix":"10.1007","volume":"44","author":[{"given":"Matthew R.","family":"Chrostek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke T.","family":"Nordquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrae L.","family":"Vandross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad A.","family":"Salkeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mannino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Hintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Caceres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manushi","family":"Vatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Emamekhoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Markey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Breitmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"De Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang G.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"5","key":"1600_CR1","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/2159-8290.CD-24-1509","volume":"15","author":"MN Sharifi","year":"2025","unstructured":"Sharifi MN, Sperger JM, Taylor AK, Tippins KE, Reese SR, Carreno V, Kaufmann KR, Chang AH, Nunamaker LA, Linebarger C, Mora-Rodriguez L (2025) High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes. Cancer Discov 15(5):969\u201387. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1509","journal-title":"Cancer Discov"},{"key":"1600_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-018-0105-8","volume":"1","author":"J Salami","year":"2018","unstructured":"Salami J, Alabi S, Willard RR et al (2018) Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol 1:100. https:\/\/doi.org\/10.1038\/s42003-018-0105-8","journal-title":"Commun Biol"},{"issue":"3","key":"1600_CR3","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley DA, Dang HX, Zhao SG et al (2018) Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174(3):758-769.e9. https:\/\/doi.org\/10.1016\/j.cell.2018.06.039","journal-title":"Cell"},{"issue":"8","key":"1600_CR4","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/s41588-024-01826-3","volume":"56","author":"SG Zhao","year":"2024","unstructured":"Zhao SG, Bootsma M, Zhou S et al (2024) Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer. Nat Genet 56(8):1689\u20131700. https:\/\/doi.org\/10.1038\/s41588-024-01826-3","journal-title":"Nat Genet"},{"issue":"8","key":"1600_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","volume":"52","author":"SG Zhao","year":"2020","unstructured":"Zhao SG, Chen WS, Li H et al (2020) The DNA methylation landscape of advanced prostate cancer. Nat Genet 52(8):778\u2013789. https:\/\/doi.org\/10.1038\/s41588-020-0648-8","journal-title":"Nat Genet"},{"issue":"26","key":"1600_CR6","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/jco.21.00169","volume":"39","author":"JM Sperger","year":"2021","unstructured":"Sperger JM, Emamekhoo H, McKay RR et al (2021) Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer. J Clin Oncol 39(26):2926\u20132937. https:\/\/doi.org\/10.1200\/jco.21.00169","journal-title":"J Clin Oncol"},{"key":"1600_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161858","author":"SG Zhao","year":"2022","unstructured":"Zhao SG, Sperger JM, Schehr JL, McKay RR, Emamekhoo H, Singh A, Schultz ZD, Bade RM, Stahlfeld CN, Gilsdorf CS, Hernandez CI (2022) A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI161858","journal-title":"J Clin Invest"},{"issue":"11","key":"1600_CR8","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/jamaoncol.2021.3987","volume":"7","author":"R Aggarwal","year":"2021","unstructured":"Aggarwal R, Rydzewski NR, Zhang L et al (2021) Prognosis associated with luminal and basal subtypes of metastatic prostate cancer. JAMA Oncol 7(11):1644\u20131652. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3987","journal-title":"JAMA Oncol"},{"issue":"12","key":"1600_CR9","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","volume":"3","author":"SG Zhao","year":"2017","unstructured":"Zhao SG, Chang SL, Erho N et al (2017) Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol 3(12):1663\u20131672. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0751","journal-title":"JAMA Oncol"},{"issue":"8","key":"1600_CR10","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1158\/1078-0432.ccr-18-3121","volume":"25","author":"SG Zhao","year":"2019","unstructured":"Zhao SG, Chen WS, Das R et al (2019) Clinical and genomic implications of luminal and basal subtypes across carcinomas. Clin Cancer Res 25(8):2450\u20132457. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-3121","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1600_CR11","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/anie.201507978","volume":"55","author":"M Toure","year":"2016","unstructured":"Toure M, Crews CM (2016) Small-molecule PROTACS: new approaches to protein degradation. Angew Chem Int Ed 55(6):1966\u20131973. https:\/\/doi.org\/10.1002\/anie.201507978","journal-title":"Angew Chem Int Ed"},{"key":"1600_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_325885","volume":"41","author":"N Coleman","year":"2021","unstructured":"Coleman N, Rodon J (2021) Taking aim at the undruggable. Am Soc Clin Oncol Educ Book 41:1\u20138. https:\/\/doi.org\/10.1200\/EDBK_325885","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1600_CR13","doi-asserted-by":"crossref","unstructured":"Yu EY, Yazji S, Katz Y, et al. A phase 1\/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer. 2024 ASCO Genitourinary Cancers Symposium: J Clinic Oncol 2024.","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS241"},{"key":"1600_CR14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-030624-110238","author":"LY Wang","year":"2025","unstructured":"Wang LY, Hung CL, Wang TC, Hsu HC, Kung HJ, Lin KH (2025) PROTACs as therapeutic modalities for drug discovery in castration-resistant prostate cancer. Annu Rev Pharmacol Toxicol. https:\/\/doi.org\/10.1146\/annurev-pharmtox-030624-110238","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"1600_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00370-8","volume":"10","author":"JL Schehr","year":"2022","unstructured":"Schehr JL, Sethakorn N, Schultz ZD et al (2022) Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer. Biomark Res 10(1):26. https:\/\/doi.org\/10.1186\/s40364-022-00370-8","journal-title":"Biomark Res"},{"issue":"3","key":"1600_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1158\/1078-0432.CCR-16-1021","volume":"23","author":"JM Sperger","year":"2017","unstructured":"Sperger JM, Strotman LN, Welsh A et al (2017) Integrated analysis of multiple biomarkers from circulating tumor cells enabled by exclusion-based analyte isolation. Clin Cancer Res 23(3):746\u2013756. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1021","journal-title":"Clin Cancer Res"},{"issue":"22","key":"1600_CR17","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1039\/c8lc00620b","volume":"18","author":"HM Pezzi","year":"2018","unstructured":"Pezzi HM, Guckenberger DJ, Schehr JL et al (2018) Versatile exclusion-based sample preparation platform for integrated rare cell isolation and analyte extraction. Lab Chip 18(22):3446\u20133458. https:\/\/doi.org\/10.1039\/c8lc00620b","journal-title":"Lab Chip"},{"issue":"20","key":"1600_CR18","doi-asserted-by":"publisher","first-page":"17065","DOI":"10.1021\/acsami.8b03627","volume":"10","author":"C Li","year":"2018","unstructured":"Li C, Yu J, Schehr J et al (2018) Exclusive liquid repellency: an open multi-liquid-phase technology for rare cell culture and single-cell processing. ACS Appl Mater Interfaces 10(20):17065\u201317070. https:\/\/doi.org\/10.1021\/acsami.8b03627","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"1600_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01252-4","volume":"14","author":"TS Rodems","year":"2022","unstructured":"Rodems TS, Juang DS, Stahlfeld CN, Gilsdorf CS, Krueger TE, Heninger E, Zhao SG, Sperger JM, Beebe DJ, Haffner MC, Lang JM (2022) SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples. Clin Epigenet 14(1):37. https:\/\/doi.org\/10.1186\/s13148-022-01252-4","journal-title":"Clin Epigenet"},{"issue":"9","key":"1600_CR20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/erc-21-0157","volume":"28","author":"M Daniel","year":"2021","unstructured":"Daniel M, Knutson PT, Sperger MJ et al (2021) AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer. Endocr Relat Cancer 28(9):645\u2013655. https:\/\/doi.org\/10.1530\/erc-21-0157","journal-title":"Endocr Relat Cancer"},{"issue":"13","key":"1600_CR21","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1158\/1078-0432.ccr-20-4616","volume":"27","author":"RR McKay","year":"2021","unstructured":"McKay RR, Kwak L, Crowdis JP et al (2021) Phase II multicenter study of enzalutamide in metastatic castration-resistant prostate cancer to identify mechanisms driving resistance. Clin Cancer Res 27(13):3610\u20133619. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-4616","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1600_CR22","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1158\/1078-0432.ccr-22-1305","volume":"29","author":"JM Sperger","year":"2023","unstructured":"Sperger JM, Helzer KT, Stahlfeld CN et al (2023) Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer. Clin Cancer Res 29(12):2324\u20132335. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-1305","journal-title":"Clin Cancer Res"},{"issue":"26","key":"1600_CR23","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/jco.21.00169","volume":"39","author":"JM Sperger","year":"2021","unstructured":"Sperger JM, Emamekhoo H, McKay RR et al (2021) Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer. J Clin Oncol 39(26):2926\u20132937. https:\/\/doi.org\/10.1200\/jco.21.00169","journal-title":"J Clin Oncol"},{"issue":"31","key":"1600_CR24","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1200\/jco.20.00348","volume":"38","author":"EC Kyriakopoulos","year":"2020","unstructured":"Kyriakopoulos EC, Heath IE, Ferrari A et al (2020) Exploring spatial-temporal changes in 18F-sodium fluoride PET\/CT and circulating tumor cells in metastatic castration-resistant prostate cancer treated with enzalutamide. J Clin Oncol 38(31):3662\u20133671. https:\/\/doi.org\/10.1200\/jco.20.00348","journal-title":"J Clin Oncol"},{"issue":"51","key":"1600_CR25","doi-asserted-by":"publisher","first-page":"84359","DOI":"10.18632\/oncotarget.12711","volume":"7","author":"E Heninger","year":"2016","unstructured":"Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR, Kosoff D, Yang B, Jarrard DF, McNeel DG, Lang JM (2016) Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget 7(51):84359","journal-title":"Oncotarget"},{"issue":"16","key":"1600_CR26","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1158\/1078-0432.ccr-17-0017","volume":"23","author":"M Kohli","year":"2017","unstructured":"Kohli M, Ho Y, Hillman WD et al (2017) Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance. Clin Cancer Res 23(16):4704\u20134715. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-0017","journal-title":"Clin Cancer Res"},{"key":"1600_CR27","doi-asserted-by":"crossref","unstructured":"Ramesh N. Abstract LBA016: Androgen receptor (AR) N-terminus-domain-binding small molecule degraders for the treatment of AR splice variant-positive castration-resistant prostate cancer. Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics: Molecular Cancer Therapeutics; 2021.","DOI":"10.1158\/1535-7163.TARG-21-LBA016"},{"issue":"7","key":"1600_CR28","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","volume":"15","author":"S Prekovic","year":"2016","unstructured":"Prekovic S, van Royen ME, Voet AR et al (2016) The effect of F877L and T878A mutations on androgen receptor response to enzalutamide. Mol Cancer Ther 15(7):1702\u20131712. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0892","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1600_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41391-022-00491-z","volume":"26","author":"G Snaterse","year":"2023","unstructured":"Snaterse G, Mies R, van Weerden WM et al (2023) Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. Prostate Cancer Prostatic Dis 26(2):293\u2013301. https:\/\/doi.org\/10.1038\/s41391-022-00491-z","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"26","key":"1600_CR30","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/JCO.23.00433","volume":"41","author":"C Dai","year":"2023","unstructured":"Dai C, Dehm SM, Sharifi N (2023) Targeting the androgen signaling axis in prostate cancer. J Clin Oncol 41(26):4267\u20134278. https:\/\/doi.org\/10.1200\/JCO.23.00433","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1600_CR31","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1200\/JCO.2024.42.16_suppl.5011","volume":"42","author":"DP Petrylak","year":"2024","unstructured":"Petrylak DP, McKean M, Lang JM et al (2024) ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): initial results of a phase 1\/2 study. J Clin Oncol 42(16_suppl):5011\u20135011. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.5011","journal-title":"J Clin Oncol"},{"key":"1600_CR32","unstructured":"Gao X, Burris III HA, Vuky J, Dreicer R, Sartor AO, Sternberg CN, Percent IJ, Hussain MH, Rezazadeh Kalebasty A, Shen J, Heath EI. Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)."}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01600-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01600-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01600-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:41:08Z","timestamp":1785498068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01600-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01600-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Disclosures JR, RK, CM, EC, AB were employees of Oncternal Therapeutics Inc during the conduct of the study. SGZ has patent applications unrelated to this work with Veracyte, consulting for, and a spouse who is an employee of Artera with stock, and stock in Exact Sciences. JML is a founder of Eolas Diagnostics, Inc.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}